ArticleJACC. Case reports2025
Massive Anterior STEMI Due to Essential Thrombocythemia Leading to Urgent Thrombocytapheresis.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyocardial infarction in essential thrombocythemia (ET) is a rare but severe complication of this myeloproliferative disorder, occurring in approximately 2% to 3% of the population. CASE SUMMARY: A 78-year-old man with calreticulin-mutated ET presented with massive anterior ST-segment elevation myocardial infarction (STEMI). Urgent coronary angiogram revealed subtotal left anterior descending artery stenosis due to heavy thrombus burden, leading to partial revascularization. His platelet count exceeded 1,200 × 10 DISCUSSION: In acute symptomatic thrombohemorrhagic complications, the American Society for Apheresis designates thrombocytapheresis as a Class II recommendation. This case describes the novel use of thrombocytapheresis in the setting of anterior STEMI with ET. TAKE-HOME MESSAGES: STEMI complicating acutely decompensated ET is life threatening, and early thrombocytapheresis should be considered in select patients. This case demonstrates the potential benefit of more aggressive cytoreductive therapy in patients with ET and underlying cardiovascular risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.